Fragment 176–191 is a synthetic segment of the human growth hormone, comprising amino acids 176 to 191 at the C‑terminus. It is specifically engineered to retain the potent lipolytic (fat‑burning) activity of full-length hGH while minimizing systemic hormonal effects. Preclinical studies in obese rodent models have shown that it significantly stimulates lipolysis—likely through upregulation of beta‑3 adrenergic receptors (ADRB3)—and enhances energy expenditure, resulting in up to 50% reduction in weight gain over a three-week period. Notably, these effects appear selective for obese subjects; lean rodents did not experience significant weight changes . Mechanistic insights reveal that Frag 176–191 activates hormone-sensitive lipase (HSL) and promotes fat oxidation while inhibiting lipogenesis, effectively tipping the metabolic balance toward fat breakdown . Importantly, unlike full-length hGH, this fragment does not raise IGF‑1 levels, disrupt carbohydrate metabolism, or impair insulin sensitivity—offering a safer metabolic profile . Beyond adipose-related effects, Frag 176–191 has also demonstrated potential in cartilage regeneration. In rabbit models of osteoarthritis, combined administration of Frag 176–191 with hyaluronic acid induced improved structural recovery in cartilage compared to hyaluronic acid alone.

Peptides are available for research purposes only.
Please review and adhere to our Terms and Conditions before ordering.